The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Gene Editing and Small Molecule Inhibitors of the RNA Binding Protein IGF2BP2/IMP2 Show its Potential as an Anti-Cancer Drug Target
Open accessAbstract
Background: The RNA-binding protein IGF2BP2/IMP2/VICKZ2/p62 is an oncofetal protein that is overexpressed in several cancer entities. Employing IMP2 knockout colorectal cancer cells, we could show the important role of IMP2 in several hallmarks of cancer. This study aimed to functionally characterize IMP2 in lung (A549, LLC1) and hepatocellular carcinoma (HepG2, Huh7) cell lines to assess its role as a potential target for these cancer entities. Methods: IMP2 knockouts were generated by CRISPR/Cas9 and its variant approach prime editing; the editing efficiency of two single guide RNAs (sgRNAs) was verified via next-generation sequencing. We studied the effect of IMP2 knockout on cell proliferation, colony formation, and migration and employed small-molecule inhibitors of IMP2. Results: Despite multiple attempts, it was not possible to generate IMP2 biallelic knockouts in A549 and Huh7 cells. Both sgRNAs showed good editing efficiency. However, edited cells lost their ability to proliferate. The attempt to generate an IMP2 biallelic knockout in LLC1 cells using CRISPR/Cas9 was successful. Monoallelic knockout cell lines of IMP2 showed a reduction in 2D cell proliferation and reduced migration. In 3D cultures, a change in morphology from compact spheroids to loose aggregates and a distinct reduction in the colony formation ability of the IMP2 knockouts was observed, an effect that was mimicked by previously identified IMP2 inhibitor compounds that also showed an inhibitory effect on colony formation. Conclusions: Our in vitro target validation supports that IMP2 is essential for tumor cell proliferation, migration, and colony formation in several cancer entities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Homozygous IGF2BP2 knockout in lung cells led to a complete halt of proliferation [85].”
From IMPlications of IMP2 in RNA Biology and Disease (2025) · cites this paper as [85]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Knockout of IMP2 in CRC cell lines demonstrated that heterozygous deletion led to proliferative deficiency [85].”
From IMPlications of IMP2 in RNA Biology and Disease (2025) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IMP2 is significantly overexpressed in colorectal cancer (CRC) cells and patient samples, highlighting its upregulation in the disease.”
From IMPlications of IMP2 in RNA Biology and Disease (2025) · cites this paper as [85]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The anti-proliferative effects of these IMP2 inhibitor compounds on colorectal cancer and lung cancer cell lines were only partially rescued by biallelic knockout of IGF2BP2, suggesting that these compounds may have additional off-targets [85,126].”
From IMPlications of IMP2 in RNA Biology and Disease (2025) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Search-and-replace genome editing without double-strand breaks or donor DNA
Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1711-4 · Cited by 4,767
CRISPResso2 provides accurate and rapid genome editing sequence analysis
Clement, K., Rees, H., Canver, M. C., Gehrke, J. M., Farouni, R., Hsu, J. Y., Cole, M. A., Liu, D. R., Joung, J. K., Bauer, D. E., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0032-3 · Cited by 1,660
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future
Uddin, F., Rudin, C. M., & Sen, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01387 · Cited by 581
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR
Boettcher, M., & McManus, M. T. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.028 · Cited by 516
Challenges of applying multicellular tumor spheroids in preclinical phase
Han, S. J., Kwon, S., & Kim, K. S. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01853-8 · Cited by 428
Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice
Liu, P., Liang, S.-Q., Zheng, C., Mintzer, E., Zhao, Y. G., Ponnienselvan, K., Mir, A., Sontheimer, E. J., Gao, G., Flotte, T. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22295-w · Cited by 273
CRISP-ID: decoding CRISPR mediated indels by Sanger sequencing
Dehairs, J., Talebi, A., Cherifi, Y., & Swinnen, J. V. (2016) · Scientific Reports · doi:10.1038/srep28973 · Cited by 234
Biological plasticity rescues target activity in CRISPR knock outs
Smits, A. H., Ziebell, F., Joberty, G., Zinn, N., Mueller, W. F., Clauder-Münster, S., Eberhard, D., Fälth Savitski, M., Grandi, P., Jakob, P., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0614-5 · Cited by 219 · cited 1×
“While successful editing disrupted gene integrity in the IMP2 knockout clones, the genomic effects did not consistently result in reduced RNA levels or explain the protein abundance in the CRISPR-generated knockout cell lines [30].”
BackgroundXu, X., Yu, Y., Zong, K., Lv, P., & Gu, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1470-y · Cited by 203
Cancer the‘RBP’eutics–RNA-binding proteins as therapeutic targets for cancer
Mohibi, S., Chen, X., & Zhang, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.07.001 · Cited by 199
Cited by
Li, D., Hu, S., Ye, J., Zhai, C., Liu, J., Wang, Z., Zhou, X., Chen, L., & Zhou, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212150 · Cited by 23
Multifaceted roles of insulin‑like growth factor 2 mRNA binding protein 2 in human cancer (Review)
Shen, J., & Ding, Y. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13441 · Cited by 12
Legroux, T. M., Schymik, H. S., Gasparoni, G., Mohammadi, S., Walter, J., Libert, C., Diesel, B., Hoppstädter, J., & Kiemer, A. K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1396827 · Cited by 10
Self-citationIMPlications of IMP2 in RNA Biology and Disease
Das, J., Busia-Bourdain, O., Khan, K. M., & Wolfe, A. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062415 · Cited by 3
“Homozygous IGF2BP2 knockout in lung cells led to a complete halt of proliferation [85].”
Berwanger, A., Wagner, K., Both, S., Kany, A. M., Mazlom, K., Hirsch, A. K. H., Kiemer, A. K., & Empting, M. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118624 · Cited by 3
Self-citation
Metadata
- Authors
- Chanda, S., Lepikhov, K., Dahlem, C., Schymik, H. S., Hoppstädter, J., Geber, A.-K., Wagner, K., Kessler, S. M., Empting, M., & Kiemer, A. K.
- Affiliations
- Saarland University (DE)
- Helmholtz Institute for Pharmaceutical Research Saarland (DE)
- Martin Luther University Halle-Wittenberg (DE)
- Corresponding author
- Kiemer, Alexandra K.
- ORCID
- Venue
- Frontiers in Bioscience-Landmark
- Publisher
- IMR Press
- Published
- 2024-01-23
- Volume
- 29
- Issue
- 1
- Pages
- 41-41
- ISSN
- 2768-6698 (ISSN-L)
- 2768-6701
- OpenAlex
- W4391151624
- Cited by
- 8
- References
- 38
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 2
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Frontiers in Bioscience-Landmark (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Publications of the UdS (Saarland University) (cc-by)
- Funders
- German Research Foundation (DFG, KI702)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- RNA-binding proteins, oncofetal protein, cancer drug targets, CRISPR/Cas9, prime editing, small molecule inhibitors, lung cancer, hepatocellular carcinoma, colorectal cancer, cell proliferation, cell migration, colony formation, tumor spheroids, target validation
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Antineoplastic Agents, Humans, Liver Neoplasms, RNA-Binding Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene Editing and Small Molecule Inhibitors of the RNA Binding Protein IGF2BP2/IMP2 Show its Potential as an Anti-Cancer Drug Target. https://app.cochat.ai/papers/10.31083/j.fbl2901041
- The paper
- Chanda, S., Lepikhov, K., Dahlem, C., Schymik, H. S., Hoppstädter, J., Geber, A.-K., Wagner, K., Kessler, S. M., Empting, M., & Kiemer, A. K. (2024). Gene Editing and Small Molecule Inhibitors of the RNA Binding Protein IGF2BP2/IMP2 Show its Potential as an Anti-Cancer Drug Target. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2901041
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.